arrow
D

Daphne Hompes

university hospitals leuven
H指数:23
被引数:1,730

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Reply to Taal et al. Comment on “Iasella et al. Close Follow-Up of Patients with Neurofibromatosis Type 1 Reduces the Incidence of Malignant Peripheral Nerve Sheath Tumour. Cancers 2025, 17, 1306”

回复Taal et al.对“Iasella et al. 对神经纤维瘤病1型患者的密切随访可降低恶性周围神经鞘瘤发生率的评论。Cancers 2025, 17, 1306”

2025-10-170
OAAI
ASO Visual Abstract: Examining the Impact of Biopsy Technique on Clinical and Pathologic Outcomes in Dermatofibrosarcoma Protuberans-An International, Multi-Institutional Study
2025-03-010
PRE
Examining the Impact of Biopsy Technique on Clinical and Pathologic Outcomes in Dermatofibrosarcoma Protuberans: An International, Multi-Institutional Study
2025-02-271
PRE
Current patterns of care and outcomes for dermatofibrosarcoma protuberans: An international multi-institutional collaborative
CANCER
IF5.1
2024-07-101
PRE
Recurrent and novel fusions detected by targeted RNA sequencing as part of the diagnostic workflow of soft tissue and bone tumours
2024-05-131
OAAI
Retrospective Analysis of Retroperitoneal-Abdominal-Pelvic Ganglioneuromas An International Study by the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)
2022-07-225
PRE
Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group (vol 28, pg 6882, 2021)
2022-03-170
OA
Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group
2021-03-1916
PRE
Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts

血小板衍生生长因子受体 α 抗体olaratumab在一组患者源性软组织肉瘤异种移植物中的评估

2019-07-225
OAAI
Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing
2019-06-0328
OAAI
Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation
2017-03-2352
OAAI